Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $36.81 USD
Change Today +0.68 / 1.88%
Volume 1.5M
SGEN On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

seattle genetics inc (SGEN) Snapshot

Open
$36.81
Previous Close
$36.13
Day High
$37.24
Day Low
$36.24
52 Week High
08/28/14 - $44.95
52 Week Low
01/16/15 - $30.05
Market Cap
4.6B
Average Volume 10 Days
1.0M
EPS TTM
$-0.62
Shares Outstanding
124.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SEATTLE GENETICS INC (SGEN)

seattle genetics inc (SGEN) Related Businessweek News

View More BusinessWeek News

seattle genetics inc (SGEN) Details

Seattle Genetics, Inc., a biotechnology company, develops and commercializes antibody-based therapies for the treatment of cancer. The company is developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Its lead product, ADCETRIS (brentuximab vedotin), is an ADC that is commercially available in approximately 35 countries, including the United States, Canada, Japan, and members of the European Union for relapsed Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL) in collaboration with Takeda Pharmaceutical Company Limited. The company is evaluating ADCETRIS in approximately 30 ongoing clinical trials, including Phase III trials for post-transplant HL relapse prevention, relapsed CD30-positive cutaneous T-cell lymphoma, frontline HL in combination with chemotherapy, and frontline CD30-positive mature T-cell lymphoma in combination with chemotherapy, as well as in Phase I and II studies in various lymphoma and non-lymphoma indications. In addition, it is developing a pipeline of other clinical-stage ADC programs, such as SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody technology. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie, Bayer, Celldex, Genentech, GlaxoSmithKline, Pfizer, Progenics, and Takeda, as well as with Agensys, Genmab, and OBT. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.

657 Employees
Last Reported Date: 02/27/15
Founded in 1998

seattle genetics inc (SGEN) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $759.3K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $422.1K
Chief Operating Officer
Total Annual Compensation: $472.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $448.0K
Executive Vice President of Technical Operati...
Total Annual Compensation: $378.4K
Compensation as of Fiscal Year 2014.

seattle genetics inc (SGEN) Key Developments

Seattle Genetics, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 04:20 PM

Seattle Genetics, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 04:20 PM. Venue: Westin Grand Central Hotel, New York, New York, United States.

Seattle Genetics Inc. Presents at Barclays Global Healthcare Conference, Mar-11-2015 08:30 AM

Seattle Genetics Inc. Presents at Barclays Global Healthcare Conference, Mar-11-2015 08:30 AM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Clay B. Siegall, Co-Founder, Chairman, Chief Executive Officer and President.

Seattle Genetics, Inc. Submits Supplemental Biologics License Application to the FDA Based on Data from Phase 3 AETHERA Trial of ADCETRIS

Seattle Genetics Inc. announced that it has submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) based on data from the phase 3 AETHERA trial of ADCETRIS (brentuximab vedotin) as consolidation therapy immediately following an autologous stem cell transplant (ASCT) in Hodgkin lymphoma (HL) patients at high risk of relapse. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical HL and systemic anaplastic large cell lymphoma (sALCL). ADCETRIS is approved in relapsed HL and sALCL but is currently not approved for consolidation therapy in HL patients immediately after ASCT. The supplemental BLA is based on positive results from a phase 3 clinical trial called AETHERA that were presented at the 56thAmerican Society of Hematology (ASH) Annual Meeting in December 2014. Results from the AETHERA trial in 329 HL patients at high risk of relapse included: the trial achieved its primary endpoint and demonstrated a significant increase in progression-free survival (PFS) per independent review facility, with a hazard ratio of 0.57 and a p-value of 0.001. Median PFS was 43 months for patients who received ADCETRIS versus 24 months for patients who received placebo. The two-year PFS rate was 63% in the ADCETRIS arm compared to 51% in the placebo arm; the PFS benefit was consistent across all pre-specified subgroups, including primary refractory patients, patients who relapsed within twelve months of frontline therapy and patients who relapsed after twelve months with extranodal disease; the most common adverse events in the ADCETRIS arm were peripheral sensory neuropathy (56%), neutropenia (35%), upper respiratory tract infection (26%), fatigue (24%) and peripheral motor neuropathy (23%). The most common adverse events in the placebo arm were upper respiratory tract infection (23%), fatigue (18%), peripheral sensory neuropathy (16%), cough (16%) and neutropenia (12%). 85% of patients with peripheral neuropathy on the ADCETRIS arm had resolution or improvement in symptoms with a median time to improvement of 23.4 weeks. Submission of safety data from the AETHERA trial to the FDA is a post-marketing requirement that Seattle Genetics will fulfill with this submission of the supplemental BLA.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGEN:US $36.81 USD +0.68

SGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $9.04 USD +0.05
Genmab A/S kr536.50 DKK +8.00
Insys Therapeutics Inc $60.44 USD -0.34
MorphoSys AG €64.61 EUR -0.002
Pfizer Ltd/India 2,254 INR +15.85
View Industry Companies
 

Industry Analysis

SGEN

Industry Average

Valuation SGEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.6x
Price/Book 21.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEATTLE GENETICS INC, please visit www.seattlegenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.